sign in sign up
<<
Home , Cyclophosphamide

Index to volume 2 (no. 1-10) (1999) for health professionals who care for patients

VOLUME 2 Jan-December 1999

No. 1 ...... January No. 6...... June No. 2 ...... February No. 7...... July-August No. 3 ...... March No. 8...... September-October No. 4 ...... April No. 9...... November No. 5 ...... May No. 10...... December

SUBJECT INDEX A BRAVAC dose modification Aminoglutethimide (Cytadren®) Discontinued for hepatic dysfunction deleted Protocol Drug Update, vol 2 (3) Mar Update, vol 2 (8) Sep-Oct Antiem-A deleted (replaced by SCNAUSEA) BRAVCAF cyclophosphamide dose modification Protocol Update, vol 2 (9) Nov for hepatic dysfunction deleted Protocol Antiem-B deleted (replaced by SCNAUSEA) Update, vol 2 (8) Sep-Oct Protocol Update, vol 2 (9) Nov BRAVCAP Protocols, vol 2 (5) May BRAVCLOD Protocols, vol 2 (5) May; Protocol B Update, vol 2 (8) Sep-Oct Baseline CBC for , vol 2 (7) Jul- BRAVCMF cyclophosphamide dose Aug modification for hepatic dysfunction deleted BCG Interchangeability Drug Update, vol 2 (8) Protocol Update, vol 2 (8) Sep-Oct Sep-Oct; Drug Update, vol 2 (10) Dec BRAVCMFO cyclophosphamide dose Benzydamine Pharmacare Authorisation Drug modification for hepatic dysfunction deleted Update, vol 2 (8) Sep-Oct Protocol Update, vol 2 (8) Sep-Oct BRAJAC cyclophosphamide dose modification BRAVDOC Protocol Update, vol 2 (2) Feb; Pre- for hepatic dysfunction deleted Protocol printed orders, vol 2 (3) Mar Update, vol 2 (8) Sep-Oct BRAVLEN deleted Protocol Update, vol 2 (8) BRAJCAF cyclophosphamide dose modification Sep-Oct for hepatic dysfunction deleted Protocol BRAVNAV Protocol Update, vol 2 (7) Jul-Aug; Update, vol 2 (8) Sep-Oct Protocol Update, vol 2 (8) Sep-Oct BRAJCEF Protocols, vol 2 (5) May; Patient BRAVPAM Protocol Update, vol 2 (7) Jul-Aug; Handouts, vol 2 (5) May Protocol Update, vol 2 (8) Sep-Oct BRAJCMF cyclophosphamide dose modification BRAVTAX Protocol Update, vol 2 (4) Apr; for hepatic dysfunction deleted Protocol Protocol Update, vol 2 (8) Sep-Oct Update, vol 2 (8) Sep-Oct (U)BRAVTR Protocol Update, vol 2 (3) Mar; BRAJCMFO cyclophosphamide dose Protocol Update, vol 2 (8) Sep-Oct; revised modification for hepatic dysfunction deleted Protocol Update, vol 2 (9) Nov Protocol Update, vol 2 (8) Sep-Oct

British Columbia Cancer Agency  Provincial Systemic Therapy Program Update  Index to Vol. 2 (No. 1-10) 1999

SUBJECT INDEX

(U)BRAVTRAP replaces UBRAVTRPA Protocol CNPLATFU deleted Protocols, vol 2 (5) May Update, vol 2 (8) Sep-Oct (U)CNTEMOZ Protocol Update, vol 2 (10) Dec BRAVTRAP replaces UBRAVTRAP Protocol CNVCD2 deleted (replaced by CNCCV) Update, vol 2 (Sup 1) Nov Protocol Update, vol 2 (9) Nov (U)BRAVTRPA Protocol Update, vol 2 (3) Mar; Communities Oncology Network Annual replaced by (U)BRAVTRAP Protocol Meeting Continuing Education, vol 2 (8) Update, vol 2 (8) Sep-Oct Sep-Oct; Continuing Education, vol 2 (9) BRINFCAF cyclophosphamide dose Nov modification for hepatic dysfunction deleted Cyclophosphamide Cancer Drug Manual, vol 2 Protocol Update, vol 2 (8) Sep-Oct (8) Sep-Oct BRLA2 cyclophosphamide dose modification for Cyproterone 50 mg tablets Pharmacy Contract hepatic dysfunction deleted Protocol Update, vol 2 (5) May Update, vol 2 (8) Sep-Oct Bundle proposal for (Camptosar®) D and solution (Pharmorubicin Delisting Operational Supplies Benefit Drug list, PFS®) from Pharmacia and Upjohn vol 2 (3) Mar accepted BCHS Contract, vol 2 (3) Mar; vol Patient Handouts, vol 2 (3) Mar 2 (4) Apr; Protocols, vol 2 (5) May Diet and Cancer: Looking Beyond 2000

Continuing Education, vol 2 (6) Jun C Diethylstilbestrol (DES) Shortage Drug Update, - Warfarin Interaction Drug vol 2 (7) Jul-Aug; Drug Update, vol 2 (9) Nov Update, vol 2 (3) Mar; Benefit Drug List, vol 2 (5) May; Patient Handouts, vol 2 (5) May; (Taxotere®) Requires non-PVC Patient Handouts, vol 2 (10) Dec Equipment Drug Update, vol 2 (2) Feb; Patient Handouts, vol 2 (3) Mar and Benefit Drug List, vol 2 (2) Feb Caring for the Patient Receiving E Chemotherapy: Course & Practicum Nursing Emergency Aid Program, vol 2 (6) Jun Practice, vol 2 (3) Mar Infusions Drug Update, vol 2 (4) Apr; wafer (Gliadel®) Health Canada IV 20 mg/ml Pharmacy Contract Update, vol Approvals, vol 2 (3) Mar 2 (5) May CEF Benefit Drug List, vol 2 (5) May Chemotherapy Extravasation Policy (Patient F Care Policy III-20) Provincial Systemic (New) Fax number for "Undesignated Therapy Program, vol 2 (9) Nov Indications", vol 2 (6) Jun Clinical Training Awards Continuing Education, Filgrastim (G-CSF) Nursing Practice Tips, vol 2 vol 2 (3) Mar (8) Sep-Oct; (G-CSF, Neupogen®)Nursing Clodronate Benefit Drug List, vol 2 (5) May; Practice Tips, vol 2 (9) Nov Patient Handouts, vol 2 (5) May; Focus On, Benefit Drug List, vol 2 (5) May; vol 2 (5) May Drug Update, vol 2 (8) Sep-Oct CNCCV replaces CNVCD2 Protocol Update, vol 5- 50 mg/ml Pharmacy Contract 2 (9) Nov Update, vol 2 (5) May; Bulk Vials Drug CNFUR96 deleted Protocols, vol 2 (5) May Update, vol 2 (7) Jul-Aug (U)CNIME Protocol Update, vol 2 (9) Nov Formestane Drug Update, vol 2 (8) Sep-Oct CNLOGRA deleted Protocols, vol 2 (5) May

British Columbia Cancer Agency  Provincial Systemic Therapy Program Update  Index to Vol. 2 (No. 1-10) 1999

SUBJECT INDEX

G GOOVCATM Protocol Update, vol 2 (1) Jan; vol (Filgrastim) G-CSF Nursing Practice Tips, vol 2 2 (4) Apr; Protocol Update, vol 2 (8) Sep- (8) Sep-Oct Oct; replaced GOOVMHI Protocol Update, GIA Protocol Update, vol 2 (1) Jan vol 2 (9) Nov GIEFUP Protocol Update, vol 2 (7) Jul-Aug; GOOVCATX Protocol Update, vol 2 (1) Jan; Protocol Update, vol 2 (8) Sep-Oct Protocol Update, vol 2 (2) Feb; vol 2 (4) Apr; Protocol Update, vol 2 (8) Sep-Oct GIENDO1 Protocol Update, vol 2 (1) Jan GOOVMHI deleted (replaced by a GOOVCATM) GIENDO2 Protocol Update, vol 2 (1) Jan; Protocol update, vol 2 (9) Nov Protocol Update, vol 2 (4) Apr GOOVTAX3 Protocol Update, vol 2 (3) Mar; vol GIFFAD Protocol Update, vol 2 (1) Jan 2 (4) Apr; Protocol Update, vol 2 (8) Sep-Oct GIFUA Protocol Update, vol 2 (1) Jan; GOOVTOP Protocols, vol 2 (5) May Protocols, vol 2 (5) May, revised Protocol Update, vol 2 (9) Nov (U)GOOVTOP Protocol Update, vol 2 (4) Apr; reclassified to Class II Protocols, vol 2 (5) GIFUC Protocol Update, vol 2 (1) Jan; revised May Protocol Update, vol 2 (9) Nov Goserelin (Zoladex®) injections Nursing GIFUFA Protocol Update, vol 2 (1) Jan Practice Tips, vol 2 (9) Nov GIFUINF Protocol Update, vol 2 (1) Jan Granisetron Pharmacare Authorisation Drug (U)GIFUIP Protocol Update, vol 2 (10) Dec Update, vol 2 (9) Nov GIFUL deleted Protocol Update, vol 2 (6) Jun GUBCG Protocol Update, vol 2 (9) Nov GIFUR2 Protocol Update, vol 2 (1) Jan GUBCV Protocol Update, vol 2 (8) Sep-Oct GIIR Protocol Update, vol 2 (1) Jan; Protocol GUBEP Protocol Update, vol 2 (2) Feb; Protocol Update, vol 2 (7) Jul-Aug Update, vol 2 (8) Sep-Oct; Protocol Update, (U)GIIRNALT Protocol Update, vol 2 (3) Mar vol 2 (10) Dec GIFUIP Protocol Update, vol 2 (3) Mar GUBMVAC renamed GUMVAC Protocol GIOCTLAR Protocol Update, vol 2 (7) Jul-Aug Update, vol 2 (8) Sep-Oct GIPGEM Protocol Update, vol 2 (1) Jan GUBP Protocol Update, vol 2 (8) Sep-Oct GIRAI Protocol Update, vol 2 (1) Jan GUBPV Protocol Update, vol 2 (8) Sep-Oct GIRALT Protocol Update, vol 2 (1) Jan; GUCMV Protocol Update, vol 2 (8) Sep-Oct Protocols, vol 2 (5) May GUEMCYT Protocol Update, vol 2 (8) Sep-Oct GIRFLOW, Protocol Update, vol 2 (2) Feb GUEP Protocol Update, vol 2 (8) Sep-Oct; GIRLAIFF Protocol Update, vol 2 (3) Mar Protocol Update, vol 2 (10) Dec Glass Ampoules Nursing Practice Tips, vol 2 (7) GUHIPE2 deleted Protocol Update, vol 2 (8) Jul-Aug Sep-Oct (Carmustine wafer) Gliadel® Health Canada GUKIFN Protocol Update, vol 2 (9) Nov Approvals, vol 2 (3) Mar GUMVAC (formerly GUBMVAC) Protocol GOCAT Preprinted Orders, vol 2 (1) Jan Update, vol 2 (8) Sep-Oct GOCXCISR Protocol Update, vol 2 (4) Apr; GUMXP Protocol Update, vol 2 (2) Feb; renamed Protocols, vol 2 (5) May renamed GUPMX Protocol Update, vol 2 (8) GOCXRADC Protocols, vol 2 (5) May Sep-Oct GOENDCAT Protocol Update, vol 2 (2) Feb; vol GUPM Protocol Update, vol 2 (8) Sep-Oct 2 (4) Apr; Protocol Update, vol 2 (8) Sep-Oct GUPMX (formerly GUMXP) Protocol Update, vol GOSMCC2 Protocol Update, vol 2 (9) Nov 2 (8) Sep-Oct GUVEIP Protocol Update, vol 2 (8) Sep-Oct

British Columbia Cancer Agency  Provincial Systemic Therapy Program Update  Index to Vol. 2 (No. 1-10) 1999

SUBJECT INDEX

GUVIP2 Protocol Update, vol 2 (8) Sep-Oct; L Protocol Update, vol 2 (10) Dec (Phase III Double Blind Study of) Letrozole versus in Women with Primary H Completing Five or More HER-2 neu Testing Hot Topics, vol 2 (3) Mar Years of Adjuvant Tamoxifen (NCIC CTG (Trastuzumab) Herceptin® Hot Topics, vol 2 (3) MA17) Update, vol 2 (2) Feb Mar; Patient Handouts, vol 2 (5) May; Drug LUALTL cyclophosphamide dose modification Update, vol 2 (8) Sep-Oct for hepatic dysfunction deleted Protocol HNDE Protocol Update, vol 2 (7) Jul-Aug Update, vol 2 (8) Sep-Oct HNE +/- C deleted Protocol Update, vol 2 (7) LUCAV cyclophosphamide dose modification for Jul-Aug hepatic dysfunction deleted Protocol Update, vol 2 (8) Sep-Oct HNF Protocol Update, vol 2 (7) Jul-Aug; deleted (replaced by HNFUFA) Protocol Update, vol LUCAVESE renamed LUPAVESE Protocol 2 (9) Nov Update, vol 2 (8) Sep-Oct HNFUA Protocol Update, vol 2 (7) Jul-Aug LUCAVESL renamed LUPAVESL Protocol Update, vol 2 (8) Sep-Oct HNFUFA (replaced HNF) Protocol Update, vol 2 (9) Nov Lung Conference Videos Available, vol 2 (3) Mar HNFUP Protocol Update, vol 2 (7) Jul-Aug LUPE Protocol Update, vol 2 (8) Sep-Oct HNH Protocol Update, vol 2 (7) Jul-Aug LUPESL Protocol Update, vol 2 (8) Sep-Oct HNM Protocol Update, vol 2 (6) Jun; Protocol Update, vol 2 (7) Jul-Aug LUPOE Protocol Update, vol 2 (8) Sep-Oct HNPE Protocol Update, vol 2 (9) Nov LUVIN Protocol Update, vol 2 (8) Sep-Oct; Protocol Update, vol 2 (10) Dec Hypercalcemia Guidelines revised, vol 2 (6) Jun LYACOP6 Protocol Update, vol 2 (10) Dec

LYACOP12 Protocol Update, vol 2 (8) Sep-Oct; I Protocol Update, vol 2 (10) Dec Index BCCA Protocol Summary Protocol LYCSA Protocol Update, vol 2 (3) Mar Update, vol 2 (1) Jan LYFLU Protocol Update, vol 2 (3) Mar; Interferon Pharmacy Contract Update, vol 2 (5) Protocols, vol 2 (5) May; Protocol Update, May; Benefit Drug List, vol 2 (7) Jul-Aug vol 2 (8) Sep-Oct 7th International Symposium on Oncology LYHDMTX Protocol Update, vol 2 (8) Sep-Oct Pharmacy Practice Continuing Education, vol 2 (7) Jul-Aug LYPALL Protocol Update, vol 2 (10) Dec 8th International Symposium on Oncology LYRITUX Protocol Update, vol 2 (2) Feb Pharmacy Practice Continuing Education, LYSNCC Protocol Update, vol 2 (8) Sep-Oct vol 2 (7) Jul-Aug IV Set Up Nursing Practice Tips, vol 2 (2) Feb M MA17 Letrozole versus placebo Clinical Trial J Update, vol 2 (2) Feb Mechlorethamine Patient Handouts, vol 2 (2) Feb

Miscellaneous supplies Benefit Drug List, vol 2 (7) Jul-Aug K Mithramycin () Drug Update, vol 2 (9)

Nov

British Columbia Cancer Agency  Provincial Systemic Therapy Program Update  Index to Vol. 2 (No. 1-10) 1999

SUBJECT INDEX

Mitomycin concentration Drug Update, vol 2 (2) Cancer Completing Five or More Years of Feb Adjuvant Tamoxifen (NCIC CTG MA17) (U)MOHDMTX Protocol Update, vol 2 (8) Sep- Clinical Trial Update, vol 2 (2) Feb Oct (Oncology Drug Adjudication Plan) Pharmanet MOIT Protocol Update, vol 2 (3) Mar; Protocols, vol 2 (3) Mar vol 2 (5) May Premedication Sequencing Nursing Practice MYPAM Protocol Update, vol 2 (4) Apr; Tips, vol 2 (2) Feb Protocols, vol 2 (5) May; Protocol Update, Preprinted Orders, vol 2 (8) Sep-Oct vol 2 (8) Sep-Oct (New) Provincial Drug Information Coordinator, vol 2 (8) Sep-Oct N National Oncology Pharmacy Symposium Q Toronto, Apr 24, 1999 Continuing Education, vol 2 (3) Mar R Normal Saline Standard Carrier Solution Drug Benefit Drug List, vol 2 (5) May; Update, vol 2 (4) Apr Patient Handouts, vol 2 (5) May; (Tomudex®) Eligibility Drug Update, vol 2 O (7) Jul-Aug Octreotide depot Health Canada Approvals, vol Patient Handouts, vol 2 (9) Nov 2 (3) Mar; (Long-acting) Benefit Drug List, vol 2 (7) Jul-Aug; Patient Handouts, vol 2 (7) S Jul-Aug SAAJADIC Protocol Update, vol 2 (9) Nov (New) Oncology Drug Budget for 1999/2000 Stop Press, vol 2 (4) Apr (Long-acting Octreotide) Sandostatin LAR® Benefit Drug List, vol 2 (7) Jul Ondansetron orally disintegrating tablet (Zofran ODT®) Health Canada Approvals, vol 2 (5) SAVIM Protocol Update, vol 2 (8) Sep-Oct May SCHYPCAL Protocol Update, vol 2 (6) Jun; OSHDMTX Protocol Update, vol 2 (6) Jun; Protocol Update, vol 2 (9) Nov Protocol Update, vol 2 (8) Sep-Oct SCNAUSEA Protocol Update, vol 2 (8) Sep-Oct; OutBound Infuser Caution, vol 2 (7) Jul-Aug replaces Antiem-A and Antiem-B Protocol Update, vol 2 (9) Nov

Sharp or Contaminated Supplies Disposal P Patient Handouts, vol 2 (8) Sep-Oct; revised (Carboplatin and) Paclitaxel Benefit Drug List, Nursing Practice Tips vol 2 (8) Sep-Oct vol 2 (2) Feb; (Taxol®) Administration Signing Cytotoxic Orders Drug Update, vol 2 (4) Nursing Practice Tips, vol 2 (2) Feb; Apr Administration Update Nursing Practice, vol 2 (4) Apr; Cancer Drug Manual, vol 2 (8) Sep-Oct T Pamidronate Benefit Drug List, vol 2 (5) May; Tamoxifen Benefit Drug List, vol 2 (2) Feb Patient Handouts, vol 2 (5) May; Benefit (Paclitaxel) Taxol® Administration Nursing Drug List, vol 2 (7) Jul-Aug Practice Tips, vol 2 (2) Feb; Administration Panda System Replacement Communities Update Nursing Practice, vol 2 (4) Apr Oncology Network, vol 2 (8) Sep-Oct (Docetaxel) Taxotere® Requires non-PVC Phase III Double Blind Study of Letrozole versus Equipment Drug Update, vol 2 (2) Feb Placebo in Women with Primary Breast Drug Update, vol 2 (10) Dec

British Columbia Cancer Agency  Provincial Systemic Therapy Program Update  Index to Vol. 2 (No. 1-10) 1999

SUBJECT INDEX

(Raltitrexed) Tomudex® Eligibility Drug Update, Z vol 2 (7) Jul-Aug (Ondansetron orally disintegrating tablet) Zofran Benefit Drug List, vol 2 (5) May; ODT® Health Canada Approvals, vol 2 (5) Patient Handouts, vol 2 (5) May May Trastuzumab (Herceptin®) Hot Topics, vol 2 (3) Mar; Patient Handouts, vol 2 (5) May; Drug Update, vol 2 (8) Sep-Oct; Benefit Drug List, vol 2 (Sup 1) Nov; Focus On, vol 2 (Sup 1) Tympanic membrane thermometers Nursing Practice Tips, vol 2 (9) Nov

U UBRAVTR Protocol Update, vol 2 (3) Mar; Protocol Update, vol 2 (8) Sep-Oct; revised Protocol Update, vol 2 (9) Nov UBRAVTRAP replaces UBRAVTRPA Protocol Update, vol 2 (8) Sep-Oct UBRAVTRPA Protocol Update, vol 2 (3) Mar; Protocols, vol 2 (5) May; replaced by (U)BRAVTRAP Protocol Update, vol 2 (8) Sep-Oct UCNIME Protocol Update, vol 2 (9) Nov UCNTEMOZ Protocol Update, vol 2 (10) Dec UGIFUIP Protocol Update, vol 2 (10) Dec UGIIRNALT Protocol Update, vol 2 (3) Mar UGOOVTOP Protocol Update, vol 2 (4) Apr; reclassified to Class II Protocols, vol 2 (5) May ULYRITUX Protocol Update, vol 2 (3) Mar; Protocol Update, vol 2 (7) Jul-Aug UMOHDMTX Protocol Update, vol 2 (8) Sep-Oct

V Labeling Drug Update, vol 2 (8) Sep- Oct Benefit Drug List, vol 2 (7) Jul-Aug W Warfarin Patient Handouts, vol 2 (3) Mar; (Capecitabine -) Interaction, vol 2 (3) Mar; Patient Handouts, vol 2 (8) Sep-Oct

X

Y

British Columbia Cancer Agency  Provincial Systemic Therapy Program Update  Index to Vol. 2 (No. 1-10) 1999